Classification of Topical Drug Products
A Way Forward to Reduce Regulatory Burden

Vinod P. Shah, Flavian S. Rădulescu, Dalia S. Miron, Avraham Yacobi

FY 2017 Generic Drug Research Public Workshop, May 3rd 2017

Silver Spring, MD. May 3, 2017
Topical Drug Classification System (TCS)

• **TCS** is a framework for classifying topical drug products based on its qualitative and quantitative composition, microstructure arrangements of matter and *in vitro* release (IVR).

• **TCS** when applied will help in approval of generic topical drug products, without conducting *in vivo* studies, but assuring product safety and efficacy.

• Topical drug products are classified into 4 classes.
Topical Drug Classification System, TCS

Q1, Q2 Same
Q3 Same
TCS class 1

Q1, Q2 Same
Q3 Different
TCS class 2

Q1, Q2 Different
Q3 Same
TCS class 3

Q1, Q2 Different
Q3 Different
TCS class 4

BCS and TCS

Oral drug products

BCS
- High Permeability
  - High Solubility
    - BCS class 1
  - Low Solubility
    - BCS class 2
- Low Permeability
  - High Solubility
    - BCS class 3
  - High Solubility
    - BCS class 4

Topical drug products

TCS
- Q1, Q2 Same
  - Q3 Same
    - TCS class 1
  - Q3 Different
    - TCS class 2
- Q1, Q2 Different
  - Q3 Same
    - TCS class 3
  - Q3 Different
    - TCS class 4

↑ Biowaiver
↑ BE
↑ Biowaiver
↑ BE

Acyclovir Cream
Studies in Progress to validate TCS

• 12 formulations are prepared with changes in manufacturing process or composition to yield drug products in TCS class 1, 2 or 3.
• We will be conducting
  - *in vitro* release tests (IVRT), *in vitro* permeation test (IVPT),
  - Assessment of Q3, Microstructure measurements, Rheology.
  - *In vivo* testing – Pilot study using DPK
Moving Forward on TCS

• We would like to invite the Agency to join us on this collaborative effort and to support the present work which may facilitate the evaluation of the potential use of TCS in the development of topical drug products and their regulatory evaluation.
Conclusion

• A practical and science based classification system, TCS, for topical drug products is proposed.

• TCS will facilitate:
  - Generic product development, reduce the regulatory burden and assure product quality across all therapeutic classes.
  - Availability of topical drug products to patients and consumers at a more reasonable cost.
Thank you for your Attention